share_log

Eli Lilly and Co | DEF 14A: Definitive information statements

Eli Lilly and Co | DEF 14A: Definitive information statements

礼来 | DEF 14A:股东委托书决议
SEC announcement ·  03/22 16:28
Moomoo AI 已提取核心信息
Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach...Show More
Eli Lilly and Co (Lilly) has announced a series of significant achievements and strategic initiatives in its 2023 annual report, reflecting the company's commitment to advancing healthcare and delivering value to shareholders. The company received regulatory approvals for Omvoh, Jaypirca, and Zepbound, which address ulcerative colitis, MCL/CCL, and obesity, respectively. Lilly also reported positive results from the Trailblazer-ALZ 2 study, indicating a slowdown in Alzheimer's disease progression. The company's strong financial performance included robust shareholder returns through December 31, 2023. Lilly's community investment included over $4 billion in medicine donations in the US and $68 million in global humanitarian aid. The company's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030, with an estimated reach of 15 million patients by the time of the report. Lilly engaged with investors on topics such as drug pricing, global product access, and enterprise risks. The board proposed management initiatives for the 2024 annual meeting to eliminate the classified board structure and supermajority voting requirements in the articles of incorporation. The company's commitment to making life better for people worldwide was reiterated, with the Annual Meeting set to welcome shareholders virtually on May 6, 2024.
礼来公司(Lilly)在其2023年年度报告中宣布了一系列重大成就和战略举措,反映了公司对推进医疗保健和为股东创造价值的承诺。该公司分别针对溃疡性结肠炎、MCL/CCL和肥胖症的Omvoh、Jaypirca和Zepbound获得了监管部门的批准。礼来公司还报告了Trailblazer-ALZ 2研究的积极结果,表明阿尔茨海默氏病进展放缓。该公司强劲的财务业绩包括截至2023年12月31日的强劲股东回报。礼来公司的社区投资包括在美国的超过40亿美元的药品捐赠和6800万美元的全球人道主义援助。该公司的30x30目标旨在到2030年在资源有限的环境中改善3000万人的医疗保健,截至报告发布时,估计...展开全部
礼来公司(Lilly)在其2023年年度报告中宣布了一系列重大成就和战略举措,反映了公司对推进医疗保健和为股东创造价值的承诺。该公司分别针对溃疡性结肠炎、MCL/CCL和肥胖症的Omvoh、Jaypirca和Zepbound获得了监管部门的批准。礼来公司还报告了Trailblazer-ALZ 2研究的积极结果,表明阿尔茨海默氏病进展放缓。该公司强劲的财务业绩包括截至2023年12月31日的强劲股东回报。礼来公司的社区投资包括在美国的超过40亿美元的药品捐赠和6800万美元的全球人道主义援助。该公司的30x30目标旨在到2030年在资源有限的环境中改善3000万人的医疗保健,截至报告发布时,估计将覆盖1500万名患者。礼来就药品定价、全球产品准入和企业风险等话题与投资者进行了接触。董事会为2024年年会提出了管理举措,以取消公司章程中的机密董事会结构和绝大多数投票要求。公司重申了改善全球人民生活的承诺,年会定于2024年5月6日以虚拟方式欢迎股东。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息